{"disease":{"id":"advanced-solid-tumors-non-small-cell-lung-cancer-melanoma","name":"advanced solid tumors non small cell lung cancer melanoma"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"pf-07820435","indication_name":"Advanced solid tumors (non-small-cell lung cancer, melanoma)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07820435","generic_name":"pf-07820435","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"SARS-CoV-2 3CL protease (main protease) and/or cellular proteases in oncology indications","drug_class":"Protease inhibitor","quality_score":null,"revenue":null,"mechanism":"PF-07820435 inhibits viral or cellular proteases to disrupt essential enzymatic processes required for viral replication or tumor cell survival."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT02729298","title":"First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"Sumitomo Pharma America, Inc.","has_results":false},{"nct_id":"NCT03319459","title":"FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT06448364","title":"A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Pfizer","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}